Overall rank by patents
#35,455
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Gladius Pharmaceuticals Corporation
USPTO PatentsView assignee record - 7 granted patents across 4 technology areas, active 2016–2021. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
7
Total patents granted
4
CPC technology areas
22.7
Avg claims per patent
-83%
5-year filing velocity
The verdict
Gladius holds 7 US patents across 4 technology areas, rank #35,455 of 50,000 tracked assignees.
- #35,455
- of 50,000 US assignees by volume
- Top 75%
- by Innovation Score (27.9/100)
- 22.7
- avg claims per patent
- -83%
- filing velocity, last 5 yrs
Portfolio overview
Gladius Pharmaceuticals Corporation has been granted 7 US utility patents between 2016 and 2021, placing Gladius Pharmaceuticals Corporation at rank #35,455 across all assignees tracked by PlainPatent. This portfolio spans 4 distinct Cooperative Patent Classification (CPC) subclasses, averaging 22.7 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, Gladius Pharmaceuticals Corporation is one of the more focused assignees in the PatentsView dataset. By volume, Gladius sits between Gigadevice Semiconductor (shanghai) Inc. (7 patents, rank #35,451) and Glico Nutrition Co., Ltd. (7 patents, rank #35,459) - the closest US assignees by grant volume. The composite Innovation Score of 27.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 1 grants, compared with 6 in the 2015–2019 window, a -83% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Gladius Pharmaceuticals Corporation's 22.7 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while specialization in 4 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Gladius Pharmaceuticals Corporation against peers pursuing similar technology classes.
Who files at Gladius's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Gigadevice Semico…
GIGADEVICE SEMICONDUCTOR (SHANGHAI) INC.
7 patents
- Giletta S P A
GILETTA S.P.A.
7 patents
- GKN Aerospace Tra…
GKN Aerospace Transparency Systems, Inc.
7 patents
- GL & V Luxembourg…
GL & V Luxembourg Sàrl
7 patents
- Glanbia Nutrition…
GLANBIA NUTRITIONALS(IRELAND) LTD.
7 patents
- Gleason Metrology…
GLEASON METROLOGY SYSTEMS CORPORATION
7 patents
- Glenn LANE Family…
GLENN LANE FAMILY LIMITED LIABILITY LIMITED PARTNERSHIP
7 patents
- Glico Nutrition
GLICO NUTRITION CO., LTD.
7 patents
- Gladius Pharmaceu… ◀
GLADIUS PHARMACEUTICALS CORPORATION
7 patents
What this shows Gladius holds 7 patents at rank #35,455, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Gladius
By rank, the assignees closest to #35,455 in granted patent volume.
- Gigadevice Semiconductor (shanghai) Inc. #35,451 · 7 patents
- Giletta S.p.a. #35,452 · 7 patents
- GKN Aerospace Transparency Systems, Inc. #35,453 · 7 patents
- GL & V Luxembourg Sàrl #35,454 · 7 patents
- Glanbia Nutritionals(ireland) Ltd. #35,456 · 7 patents
- Gleason Metrology Systems Corporation #35,457 · 7 patents
- Glenn LANE Family Limited Liability Limited Partnership #35,458 · 7 patents
- Glico Nutrition Co., Ltd. #35,459 · 7 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Gladius's primary technology class.
- The Regents Of The University Of California 1,387 in class
- Novartis Ag 1,071 in class
- Merck Sharp & Dohme Llc 889 in class
- Bristol-myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board Of Regents Of The University Of Texas System 744 in class
- Hoffmann-la Roche Inc. 722 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 721 in class
Gladius's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
28 Top 75% higher than 25% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 1 | 14.3% |
| 2017 | 1 | 14.3% |
| 2018 | 3 | 42.9% |
| 2019 | 1 | 14.3% |
| 2021 | 1 | 14.3% |
Which technologies does Gladius Pharmaceuticals Corporation patent most?
Top 4 of 4 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Complex
Velocity Declining
Frequently Asked Questions
How many patents does Gladius Pharmaceuticals Corporation hold?
Gladius Pharmaceuticals Corporation holds 7 US granted patents filed between 2016 and 2021, spanning 4 technology areas.
What is Gladius Pharmaceuticals Corporation's Innovation Score?
Gladius Pharmaceuticals Corporation has an Innovation Score of 27.9 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Gladius Pharmaceuticals Corporation focus on?
Gladius Pharmaceuticals Corporation's top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 7 patents. The company has filed patents in 4 CPC subclasses total.
Is Gladius Pharmaceuticals Corporation's patent filing rate increasing or decreasing?
Gladius Pharmaceuticals Corporation's recent filing velocity is -83% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Gladius Pharmaceuticals Corporation's patents?
Gladius Pharmaceuticals Corporation's patents average 22.7 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Gladius Pharmaceuticals Corporation patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Gladius's 7 grants land it in the top 75% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Gladius ranks #35,455 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.